SIV Vpx is essential for macrophage infection but not for development of AIDS

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Westmoreland, Susan V ^a   Converse, A Peter ^a   Hrecka, Kasia ^c   Hurley, Mollie ^a,d   Knight, Heather ^a   Piatak, Michael ^b   Lifson, Jeffrey ^b   Mansfield, Keith G ^a,e   Skowronski, Jacek ^c   Desrosiers, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAIC FREDERICK INC   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Harvard Medical School New England Primate Research Center Division of Microbiology ^*  (United States)

^e NOVARTIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRAL PROTEIN X; VIRUS PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL LINEAGE; COLON; CONTROLLED STUDY; DELETION MUTANT; GASTROINTESTINAL MUCOSA; LYMPH NODE; LYMPHOID TISSUE; MACROPHAGE; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SPLEEN; STRAIN DIFFERENCE; VIRUS CELL INTERACTION; VIRUS ENCEPHALITIS; VIRUS LOAD; VIRUS MUTANT; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ENCEPHALITIS, VIRAL; GENE DELETION; GENE EXPRESSION; LYMPH NODES; MACACA MULATTA; MACROPHAGES; MOLECULAR SEQUENCE DATA; MONOCYTES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN; SURVIVAL ANALYSIS; VIRAL LOAD; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

EID: 84908000244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084463     Document Type: Article

References (51)

1. Tristem M, Marshall C, Karpas A, Hill F (1992) Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J 11: 3405-3412.
2. Hirsch VM, Sharkey ME, Brown CR, Brichacek B, Goldstein S, et al. (1998) Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med 4: 1401-1408. (Pubitemid 28553463)
3. Tristem M, Purvis A, Quicke DL (1998) Complex evolutionary history of primate lentiviral vpr genes. Virology 240: 232-237. (Pubitemid 28384229)
4. Sharp PM, Bailes E, Stevenson M, Emerman M, Hahn BH (1996) Gene acquisition in HIV and SIV. Nature 383: 586-587.
5. Fletcher TM, 3rd, Brichacek B, Sharova N, Newman MA, Stivahtis G, et al. (1996) Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 15: 6155-6165. (Pubitemid 26397887)
6. Campbell BJ, Hirsch VM (1997) Vpr of simian immunodeficiency virus of African green monkeys is required for replication in macaque macrophages and lymphocytes. J Virol 71: 5593-5602. (Pubitemid 27258238)
7. Ayinde D, Maudet C, Transy C, Margottin-Goguet F (2010) Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirology 7: 35.
8. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654-657.
9. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, et al. (2012) SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nature immunology 13: 223-228.
10. Goujon C, Schaller T, Galao RP, Amie SM, Kim B, et al. (2013) Evidence for IFNalpha-induced, SAMHD1-independent inhibitors of early HIV-1 infection. Retrovirology 10: 23.
11. Bloch N, O'Brien M, Norton TD, Polsky SB, Bhardwaj N, et al. (2013) HIV Type 1 Infection of Plasmacytoid and Myeloid Dendritic Cells Is Restricted by High Levels of SAMHD1 and Cannot be Counteracted by Vpx. AIDS research and human retroviruses.
12. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, et al. (2008) Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 4: e1000059.
13. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, et al. (2008) Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog 4: e1000057.
14. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474: 658-661.
15. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, et al. (2012) SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nature medicine 18: 1682-1687.
16. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, et al. (2012) SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology 9: 87.
17. Puigdomenech I, Casartelli N, Porrot F, Schwartz O (2013) SAMHD1 restricts HIV-1 cell-to-cell transmission and limits immune detection in monocyte-derived dendritic cells. Journal of virology 87: 2846-2856.
18. Aggarwal A, McAllery S, Turville SG (2013) Revising the Role of Myeloid cells in HIV Pathogenesis. Current HIV/AIDS reports 10: 3-11.
19. Gibbs JS, Regier DA, Desrosiers RC (1994) Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS research and human retroviruses 10: 607-616. (Pubitemid 24186732)
20. Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, et al. (1995) Progression to AIDS in the absence of a gene for vpr or vpx. J Virol 69: 2378-2383.
21. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, et al. (1998) Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 72: 1431-1437. (Pubitemid 28116930)
22. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC (1996) Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. Journal of virology 70: 3724-3733. (Pubitemid 26157352)
23. Ringler DJ, Hunt RD, Desrosiers RC, Daniel MD, Chalifoux LV, et al. (1988) Simian immunodeficiency virus-induced meningoencephalitis: natural history and retrospective study. Annals of neurology 23 Suppl: S101-107.
24. Desrosiers RC, Hansen-Moosa A, Mori K, Bouvier DP, King NW, et al. (1991) Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS. The American journal of pathology 139: 29-35.
25. Simon MA, Chalifoux LV, Ringler DJ (1992) Pathologic features of SIV-induced disease and the association of macrophage infection with disease evolution. AIDS research and human retroviruses 8: 327-337.
26. Newstein MC, Desrosiers RC (2001) Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in Rhesus monkeys. J Infect Dis 184: 1262-1267. (Pubitemid 33055570)
27. Ling B, Veazey RS, Luckay A, Penedo C, Xu K, et al. (2002) SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS 16: 1489-1496. (Pubitemid 34804213)
28. Mansfield K, Lang SM, Gauduin MC, Sanford HB, Lifson JD, et al. (2008) Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol 82: 4135-4148. (Pubitemid 351521248)
29. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, et al. (2003) Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol 77: 6823-6835. (Pubitemid 36666876)
30. Kirchoff V, Wong S, St JS, Pari GS (2002) Generation of a life-expanded rhesus monkey fibroblast cell line for the growth of rhesus rhadinovirus (RRV). Archives of virology 147: 321-333. (Pubitemid 34159552)
31. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. The Journal of experimental medicine 185: 621-628. (Pubitemid 27098147)
32. Vallance SJ, Downes CP, Cragoe EJ, Whetton AD (1990) Granulocyte- macrophage colony-stimulating factor can stimulate macrophage proliferation via persistent activation of Na+/H+ antiport. Evidence for two distinct roles for Na+/H+ antiport activation. The Biochemical journal 265: 359-364. (Pubitemid 20041978)
33. Bagasra O, Wright SD, Seshamma T, Oakes JW, Pomerantz RJ (1992) CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America 89: 6285-6289.
34. Bergamini A, Perno CF, Dini L, Capozzi M, Pesce CD, et al. (1994) Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding. Blood 84: 3405-3412. (Pubitemid 24352903)
35. Borda JT, Alvarez X, Kondova I, Aye P, Simon MA, et al. (2004) Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. The American journal of pathology 165: 2111-2122. (Pubitemid 39578388)
36. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT (2011) Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell host & microbe 9: 46-57.
37. Wiley CA, Masliah E, Achim CL (1994) Measurement of CNS HIV burden and its association with neurologic damage. Advances in neuroimmunology 4: 319-325. (Pubitemid 24325879)
38. Masliah E, Ge N, Mucke L (1996) Pathogenesis of HIV-1 associated neurodegeneration. Critical reviews in neurobiology 10: 57-67. (Pubitemid 26283955)
39. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, et al. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS pathogens 5: e1000429.
40. Igarashi T, Donau OK, Imamichi H, Dumaurier MJ, Sadjadpour R, et al. (2003) Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. Journal of virology 77: 13042-13052. (Pubitemid 37494300)
41. Breed MW, Jordan AP, Aye PP, Lichtveld CF, Midkiff CC, et al. (2013) Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression. Journal of virology 87: 1528-1543.
42. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, et al. (2001) Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proceedings of the National Academy of Sciences of the United States of America 98: 658-663. (Pubitemid 32105099)
43. Lim ES, Fregoso OI, McCoy CO, Matsen FA, Malik HS, et al. (2012) The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell host & microbe 11: 194-204.
44. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, et al. (1990) Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248: 1109-1112.
45. Kestler HW, 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, et al. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651-662.
46. Cline AN, Bess JW, Piatak M, Jr., Lifson JD (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34: 303-312. (Pubitemid 41179592)
47. O'Neil SP, Suwyn C, Anderson DC, Niedziela G, Bradley J, et al. (2004) Correlation of acute humoral response with brain virus burden and survival time in pig-tailed macaques infected with the neurovirulent simian immunodeficiency virus SIVsmmFGb. Am J Pathol 164: 1157-1172. (Pubitemid 38387783)
48. O'Neil SP, Novembre FJ, Hill AB, Suwyn C, Hart CE, et al. (2000) Progressive infection in a subset of HIV-1-positive chimpanzees. J Infect Dis 182: 1051-1062.
49. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, et al. (2009) Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 83: 7305-7321.
50. Yearley JH, Xia D, Pearson CB, Carville A, Shannon RP, et al. (2009) Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet. Lab Invest 89: 657-667.
51. Annamalai L, Westmoreland SV, Domingues HG, Walsh DG, Gonzalez RG, et al. (2010) Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleotide reverse transcriptase inhibitors. PLoS One 5: e14429.